Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Bionanomatrix to Co-develop Genetic Analysis System

NEW YORK (GenomeWeb News) – Agilent Technologies and BioNanomatrix will team to develop an integrated genetic analysis system with applications in genotoxicity and cytogenetics assay development, and potentially DNA sequencing, the companies said today.
 
Under the agreement, the companies plan to combine BioNanomatrix’s single-molecule imaging technology to develop chips and reagents with a measurement platform developed by Agilent.
 
Philadelphia-based BioNanomatrix is currently developing nanoscale single-molecule technology that will enable identification and analysis of an entire genome, the company said. The firm recently formed a joint venture with Complete Genomics to use an $8.8 million grant from the US National Institute of Standards and Technology to develop a platform aimed at sequencing a human genome in eight hours for under $100.
 
“BioNanomatrix’s unique nanoscale whole genome imaging and analysis technology, with sensitivity at the level of the single molecule, has the potential to enable a number of important new applications for life sciences research and clinical medicine,” said Agilent GM of Life Sciences Solutions Nick Roelofs.
 
Financial terms of the agreement were not released.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.